Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):734–738. doi: 10.1128/aac.40.3.734

Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

A A Firsov 1, D Savarino 1, M Ruble 1, D Gilbert 1, B Manzano 1, A A Medeiros 1, S H Zinner 1
PMCID: PMC163189  PMID: 8851602

Abstract

The clinical outcome in patients treated with ampicillin-sulbactam may not always be predictable by disc susceptibility testing or with the MIC as determined with a constant level (4 micrograms/ml) of the beta-lactamase inhibitor (MIC1). The enzyme activities (EA) and the MICs estimated at a constant ratio of ampicillin to sulbactam of 2:1 (MIC2) for 15 TEM-1 beta-lactamase-producing strains of Escherichia coli were examined as alternatives to MIC1 as predictors of the antibacterial effects of this combined drug as studied in an in vitro model which simulates ampicillin-sulbactam pharmacokinetic profiles observed in human peripheral tissues. Integral parameters describing the area under the bacterial count-time curve (AUBC), the area between the normal growth curve, and the killing curve of bacteria exposed to antibiotic (ABBC), and the second parameter expressed as a percentage of its maximal hypothetical value (ABBC/ABBCmax) were calculated. All three parameters correlated well with EA (AUBC, r = 0.93; ABBC, r = -0.88; ABBC/ABBCmax, r = -0.91) and with MIC2 (r = 0.94, -0.94, and -0.95, respectively) but not with MIC1. Both EA and MIC2 can be considered reliable predictors of the antibacterial effect of ampicillin-sulbactam in an in vitro model. These correlations suggest that in vitro kinetic-dynamic models might be useful to reexamine established susceptibility breakpoints obtained with data based on the MIC1 (MICs obtained with constant levels of beta-lactamase inhibitors). These data also suggest that quantitative determinations of bacterial beta-lactamase production and MICs based on the component concentration ratio observed in vivo might be useful predictors of the effect of ampicillin-sulbactam and other beta-lactam-inhibitor combinations.

Full Text

The Full Text of this article is available as a PDF (236.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastone E. B., Li S. C., Ioannides-Demos L. L., Spicer W. J., McLean A. J. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother. 1993 Apr;37(4):914–917. doi: 10.1128/aac.37.4.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blaser J., Stone B. B., Zinner S. H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar;27(3):343–349. doi: 10.1128/aac.27.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blaser J., Stone B. B., Zinner S. H. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):131–137. doi: 10.1093/jac/15.suppl_a.131. [DOI] [PubMed] [Google Scholar]
  4. Firsov A. A., Chernykh V. M., Navashin S. M. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrob Agents Chemother. 1990 Jul;34(7):1312–1317. doi: 10.1128/aac.34.7.1312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Firsov A. A. In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:406–409. [PubMed] [Google Scholar]
  6. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Tisdale J. E., Pasko M. T., Mylotte J. M. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob Agents Chemother. 1989 Sep;33(9):1500–1505. doi: 10.1128/aac.33.9.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Vecoli C., Prevost F. E., Ververis J. J., Medeiros A. A., O'Leary G. P., Jr Comparison of polyacrylamide and agarose gel thin-layer isoelectric focusing for the characterization of beta-lactamases. Antimicrob Agents Chemother. 1983 Aug;24(2):186–189. doi: 10.1128/aac.24.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. White C. A., Toothaker R. D. Influence of ampicillin elimination half-life on in-vitro bactericidal effect. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):257–260. doi: 10.1093/jac/15.suppl_a.257. [DOI] [PubMed] [Google Scholar]
  10. White C. A., Toothaker R. D., Smith A. L., Slattery J. T. In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli. Antimicrob Agents Chemother. 1989 Jul;33(7):1046–1051. doi: 10.1128/aac.33.7.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wiedemann B., Jansen A. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model. J Antimicrob Chemother. 1990 Jul;26(1):71–79. doi: 10.1093/jac/26.1.71. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES